Meeting
2022 ASCO Annual Meeting
Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy.
Authors
Ryan Yong Kiat Tay
Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
Ryan Yong Kiat Tay , Joe Poh Sheng Yeong , Jeffrey Lum , Chong Boon Teo , Benjamin Kye Jyn Tan , Yiong Huak Chan , Joan RE Choo , Anand Jeyasekhran , Qing Hao Miow , Lit-Hsin Loo , Wei-Peng Yong , Raghav Sundar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4026)
DOI
10.1200/JCO.2022.40.16_suppl.4026
Abstract #
4026
Poster Bd #
14
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A comprehensive pan-cancer analysis of PD-L1 expression using clone E1L3N in Chinese patients with cancer.
First Author: Huangbin Lu
Poster
2023 ASCO Annual Meeting
Phase II study of lenvatinib plus pembrolizumab for patients with immunotherapy-naive advanced gastric cancer following first line therapy.
First Author: Deirdre Jill Cohen
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Beyond CPS for PD-L1 scoring: Genetic alterations that impact efficacy of immunotherapy in hepatocellular carcinoma (HCC).
First Author: Emil Lou
Poster
2022 ASCO Annual Meeting
Comprehensive genomic and immune profiling defines immunotherapy treatment in patients with NSCLC with low PD-L1 IHC.
First Author: Sarabjot Pabla